Biomerica (BMRA) Non-Current Deferred Tax Liability (2016 - 2017)

Biomerica (BMRA) reported Non-Current Deferred Tax Liability of $8000.0 for Q2 2017, down 84.91% on a YoY basis from $53000.0 in Q2 2016, and down 84.91% sequentially from $53000.0 in Q2 2016.

Biomerica (BMRA) Non-Current Deferred Tax Liability (2016 - 2017) Analysis & Trends

Biomerica (BMRA) has 2 years of Non-Current Deferred Tax Liability data on file, last reported at $8000.0 in Q2 2017.

  • For the quarter ending Q2 2017, Non-Current Deferred Tax Liability fell 84.91% year-over-year to $8000.0; the trailing twelve-month figure through May 2017 stood at $8000.0 (down 84.91% YoY), and the FY2017 full-year result was $8000.0, down 84.91% from the prior year.
  • Non-Current Deferred Tax Liability eased to $8000.0 in Q2 2017, from $53000.0 in the prior quarter.
  • In the past five years, Non-Current Deferred Tax Liability ranged from a high of $53000.0 in Q2 2016 to a low of $8000.0 in Q2 2017.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 201.40 Bn 194.75 Bn 6.27 Bn
2 Stryker 122.29 Bn 119.41 Bn 3.81 Bn
3 Medtronic 105.01 Bn 96.40 Bn 6.41 Bn
4 Boston Scientific 64.81 Bn 63.59 Bn 3.61 Bn
5 Edwards Lifesciences 55.28 Bn 51.60 Bn 1.29 Bn
6 Dexcom 29.06 Bn 27.94 Bn 750.30 Mn
7 Koninklijke Philips 29.02 Bn 25.93 Bn 2.07 Bn
8 GE HealthCare Technologies 28.27 Bn 26.20 Bn 1.98 Bn
9 Smith & Nephew 25.80 Bn 25.22 Bn -
10 Biomerica 4.85 Mn 3.51 Mn -44,000.00

Historic Data

Download Data
DateValue
May 31, 2017 8,000.00
May 31, 2017 8,000.00
May 31, 2016 53,000.00
May 31, 2016 53,000.00